2016 - 19th Annual Steven Galovich Memorial Student Symposium

Presentation Title

Predicting Treatment Effectiveness Among Patients with Ovarian Cancer

Student Presenter(s) and Advisor

raul torres, Lake Forest CollegeFollow

Location

Meyer Auditorium

Abstract

Ovarian cancer is the fifth-leading cause of cancer in women; afflicting 22,240 women in 2013 and an associated mortality rate of approximately 65%. Patients with ovarian cancer tend to either respond well to chemotherapy or respond very poorly. Unfortunately, there currently exists no way to determine which patients will respond well before administering treatment. Genomics presents us with the opportunity to do just this; a step toward personalized medicine. I will discuss a project that applies machine-learning methods to the gene-expression profiles of stage III and stage IV ovarian cancer patients in an effort to predict chemotherapy-resistance. Additionally, an ancillary aim of finding a candidate biomarker for disease onset is explored.

Presentation Type

Individual Presentation

Start Date

4-5-2016 9:00 AM

End Date

4-5-2016 10:15 AM

Panel

Genomics, Biostatistics, and Predictive Medicine

Panel Moderator

Cathy Benton

Field of Study for Presentation

Biology, Computer Science, Mathematics

No downloadable materials are available for this event.

Share

Import Event to Google Calendar

COinS
 
Apr 5th, 9:00 AM Apr 5th, 10:15 AM

Predicting Treatment Effectiveness Among Patients with Ovarian Cancer

Meyer Auditorium

Ovarian cancer is the fifth-leading cause of cancer in women; afflicting 22,240 women in 2013 and an associated mortality rate of approximately 65%. Patients with ovarian cancer tend to either respond well to chemotherapy or respond very poorly. Unfortunately, there currently exists no way to determine which patients will respond well before administering treatment. Genomics presents us with the opportunity to do just this; a step toward personalized medicine. I will discuss a project that applies machine-learning methods to the gene-expression profiles of stage III and stage IV ovarian cancer patients in an effort to predict chemotherapy-resistance. Additionally, an ancillary aim of finding a candidate biomarker for disease onset is explored.